Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

OBJECTIVE: The principle of replacing prandial insulin lispro with a once-weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) for type 2 diabetes inadequately controlled on a multiple daily insulin injections regimen was tested with albiglutide. RESEARCH DESIGN AND METHODS: In this treat-to-ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Nino, Antonio, Soffer, Joseph, Erskine, Lois, Acusta, Andre, Dole, Jo, Carr, Molly C., Mallory, Jason, Home, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510023/
https://www.ncbi.nlm.nih.gov/pubmed/32694215
http://dx.doi.org/10.2337/dc19-2316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510023/
https://www.ncbi.nlm.nih.gov/pubmed/32694215
http://dx.doi.org/10.2337/dc19-2316

Ejemplares similares